Literature DB >> 4045914

Site-dependent response to chemotherapy for carcinoma of the breast.

J M Whitehouse.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 4045914      PMCID： PMC1289529     

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  16 in total

1.  Adriamycin, 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC 409962) and cyclophosphamide therapy of drug-resistant metastatic breast carcinoma.

Authors:  C A Presant; A Van Amburg; C Klahr
Journal:  Cancer       Date:  1977-09       Impact factor: 6.860

2.  Phase II study of combined vincristine, adriamycin, cyclophosphamide, and methotrexate with citrovorum factor factor rescue in metastatic breast cancer.

Authors:  W Mattsson; A Arwidi; F von Eyben; C E Lindholm
Journal:  Cancer Treat Rep       Date:  1977-11

3.  Proceedings: Superiority of adriamycin over oral nitrosoureas in patients with advanced breast carcinoma. A Southwest Cancer Chemotherapy study Group study.

Authors:  J A Gottlieb; S E Rivkin; S C Spigel; B Hoogstraten; R M O'Bryan; F C Delaney; A Singhakowinta
Journal:  Cancer       Date:  1974-02       Impact factor: 6.860

4.  Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.

Authors:  S E Jones; B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-07       Impact factor: 6.860

5.  An effective low-dose intermittent cyclophosphamide, methotrexate, and 5-fluorouracil treatment regimen for metastatic breast cancer.

Authors:  R H Creech; R B Catalano; M J Mastrangelo; P F Engstrom
Journal:  Cancer       Date:  1975-04       Impact factor: 6.860

6.  Randomized trial of cyclophosphamide, doxorubicin, and 5-fluorouracil alone or alternating with a "cycle active" non-cross-resistant combination in women with visceral metastatic breast cancer: a Southeastern Cancer Study Group project.

Authors:  C L Vogel; R V Smalley; M Raney; S Krauss; J Carpenter; E Velez-Garcia; E Fishkin; S Raab; M R Moore; M Stagg
Journal:  J Clin Oncol       Date:  1984-06       Impact factor: 44.544

7.  A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy.

Authors:  J M Bull; D C Tormey; S H Li; P P Carbone; G Falkson; J Blom; E Perlin; R Simon
Journal:  Cancer       Date:  1978-05       Impact factor: 6.860

8.  Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer.

Authors:  H Y Yap; R S Benjamin; G R Blumenschein; G N Hortobagyi; C K Tashima; A U Buzdar; G P Bodey
Journal:  Cancer Treat Rep       Date:  1979-01

9.  Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.

Authors:  R H Creech; R B Catalano; D T Harris; P F Engstrom; P J Grotzinger
Journal:  Cancer       Date:  1979-01       Impact factor: 6.860

10.  Prognostic factors in metastatic breast cancer treated with combination chemotherapy.

Authors:  K D Swenerton; S S Legha; T Smith; G N Hortobagyi; E A Gehan; H Y Yap; J U Gutterman; G R Blumenschein
Journal:  Cancer Res       Date:  1979-05       Impact factor: 12.701
View more
  1 in total

1.  Treating bony metastases.

Authors:  D Dodwell; A Howell
Journal:  BMJ       Date:  1991-08-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.